The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
PONTIAC (NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease)
Open accessAbstract
Objectives The study sought to assess the primary preventive effect of neurohumoral therapy in high-risk diabetic patients selected by N-terminal pro-B-type natriuretic peptide (NT-proBNP). Background Few clinical trials have successfully demonstrated the prevention of cardiac events in patients with diabetes. One reason for this might be an inaccurate selection of patients. NT-proBNP has not been assessed in this context. Methods A total of 300 patients with type 2 diabetes, elevated NT-proBNP (>125 pg/ml) but free of cardiac disease were randomized. The "control" group was cared for at 4 diabetes care units; the "intensified" group was additionally treated at a cardiac outpatient clinic for the up-titration of renin-angiotensin system (RAS) antagonists and beta-blockers. The primary endpoint was hospitalization/death due to cardiac disease after 2 years. Results At baseline, the mean age of the patients was 67.5 ± 9 years, duration of diabetes was 15 ± 12 years, 37% were male, HbA1c was 7 ± 1.1%, blood pressure was 151 ± 22 mm Hg, heart rate was 72 ± 11 beats/min, median NT-proBNP was 265.5 pg/ml (interquartile range: 180.8 to 401.8 pg/ml). After 12 months there was a significant difference between the number of patients treated with a RAS antagonist/beta-blocker and the dosage reached between groups (p < 0.0001). Blood pressure was significantly reduced in both (p < 0.05); heart rate was only reduced in the intensified group (p = 0.004). A significant reduction of the primary endpoint (hazard ratio: 0.351; 95% confidence interval: 0.127 to 0.975, p = 0.044) was visible in the intensified group. The same was true for other endpoints: all-cause hospitalization, unplanned cardiovascular hospitalizations/death (p < 0.05 for all). Conclusions Accelerated up-titration of RAS antagonists and beta-blockers to maximum tolerated dosages is an effective and safe intervention for the primary prevention of cardiac events for diabetic patients pre-selected using NT-proBNP. (Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients [PONTIAC]; NCT00562952).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Results from several randomized controlled trials revealed that more intensive treatment of risk factors in people with increased levels of natriuretic peptides reduces the risk for symptomatic heart failure, heart failure hospitalization, and newly diagnosed left ventricular dysfunction (222,227,228).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [222]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Identification, risk stratification, and early treatment of risk factors in people with diabetes and asymptomatic stages of heart failure reduce the risk for progression to symptomatic heart failure (221,222).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [222]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Results from several randomized controlled trials revealed that more intensive treatment of risk factors in people with increased levels of natriuretic peptides reduces the risk for symptomatic heart failure, heart failure hospitalization, and newly diagnosed left ventricular dysfunction (211,216,217).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [211]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Identification, risk stratification, and early treatment of risk factors in people with diabetes and asymptomatic stages of heart failure reduce the risk for progression to symptomatic heart failure (210,211).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [211]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
(2000) · PubMed · Cited by 2,095
A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805796 · Cited by 1,939
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Mann, J. F. E., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J. M., Wang, X., Maggioni, A. P., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,579
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus
Buse, J. B., Ginsberg, H. N., Bakris, G. L., Clark, N. G., Costa, F., Eckel, R., Fonseca, V., Gerstein, H. C., Grundy, S., Nesto, R. W., et al. (2007) · Diabetes Care · doi:10.2337/dc07-9917 · Cited by 1,055
Gæde, P., Vedel, P., Parving, H.-H., & Pedersen, O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07368-1 · Cited by 981
Bakris, G. L., & Weir, M. R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.5.685 · Cited by 823
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
Haller, H., Ito, S., Izzo, J. L., Januszewicz, A., Katayama, S., Menne, J., Mimran, A., Rabelink, T. J., Ritz, E., Ruilope, L. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007994 · Cited by 792
Plasma Brain Natriuretic Peptide-Guided Therapy to Improve Outcome in Heart Failure
Patrick Jourdain, M., Jondeau, G., Funck, F., Gueffet, P., Helloco, A. L., Donal, E., Aupetit, J. F., Aumont, M. C., Galinier, M., Eicher, J. C., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.081 · Cited by 647
N-Terminal Pro–B-Type Natriuretic Peptide-Guided Treatment for Chronic Heart Failure
Lainchbury, J. G., Troughton, R. W., Strangman, K. M., FRAMPTON, C. M. A., Pilbrow, A. P., Yandle, T. G., Hamid, A., Nicholls, M. G., & Richards, M. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.095 · Cited by 351
Savarese, G., Costanzo, P., Cleland, J. G. F., Vassallo, E., Ruggiero, D., Rosano, G. M. C., & Filardi, P. P. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.011 · Cited by 196
Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes
Tarnow, L., Gall, M.-A., Hansen, B. V., Hovind, P. H., & Parving, H. ‐. (2006) · Diabetologia · doi:10.1007/s00125-006-0359-4 · Cited by 110
Savarese, G., Costanzo, P., Cleland, J. G. F., Vassallo, E., Ruggiero, D., Rosano, G. M. C., & Filardi, P. P. (2013) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2013-9-2-188-200 · Cited by 106
G�de, P., Hildebrandt, P., Hess, G., Parving, H.-H., & Pedersen, O. (2005) · Diabetologia · doi:10.1007/s00125-004-1607-0 · Cited by 105
Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes
Haller, H. G., Ito, S., Izzo, J. L., Januszewicz, A., Katayama, S., Menne, J., Mimran, A., Rabelink, T. J., Ritz, E., Ruilope, L. M., et al. (2012) · Survey of Anesthesiology · doi:10.1097/01.sa.0000412361.12996.3b · Cited by 104
Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus
Bhalla, M. A., Chiang, A., Epshteyn, V. A., Kazanegra, R., Bhalla, V., Clopton, P., Krishnaswamy, P., Morrison, L. K., Chiu, A., Gardetto, N. J., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.05.071 · Cited by 103
Huelsmann, M., Neuhold, S., Strunk, G., Moertl, D., Berger, R., Prager, R., Abrahamian, H., Riedl, M., Pacher, R., Luger, A., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn334 · Cited by 84
Self-citationACCORD and Risk-Factor Control in Type 2 Diabetes
Nilsson, P. M. (2010) · New England Journal of Medicine · doi:10.1056/nejme1002498 · Cited by 68
Grassi, G. M., Seravalle, G., Quarti‐Trevano, F., Mineo, C., Lonati, L. M., Facchetti, R., & Mancia, G. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e328337a9fd · Cited by 46
Clodi, M., Resl, M., Neuhold, S., Hülsmann, M., Vila, G., Elhenicky, M., Strunk, G., Abrahamian, H., Prager, R., Luger, A., et al. (2011) · European Journal of Preventive Cardiology · doi:10.1177/1741826711420015 · Cited by 37
Self-citationNeuhold, S., Resl, M., Huelsmann, M., Strunk, G., Adlbrecht, C., Rath, C., Prager, R., Luger, A., Clodi, M., & Pacher, R. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2011.02539.x · Cited by 19
Self-citationDawson, A., Jeyaseelan, S., Morris, A. D., & Struthers, A. D. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.05.050 · Cited by 19
Frankenstein, L., Nelles, M., Slavutsky, M., Schellberg, D., Doesch, A. O., Katus, H. A., Remppis, A. B., & Zugck, C. (2007) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2007.07.030 · Cited by 14
Research works printed but not linked: 1
- 2009, Osterreichische Diabetes Gesellschaft Diabetes Mellitus. Guidelines for the practice. Revised and expanded 2007 edition, Wien Klin Wochenschr, 121, S1
Cited by
Sorted by citations
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2021) · PubMed · doi:10.1093/eurheartj/ehab670 · Cited by 20,604
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M. L., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.025 · Cited by 3,532
Metadata
- Authors
- Huelsmann, M., Neuhold, S., Resl, M., Strunk, G., Brath, H., Francesconi, C., Adlbrecht, C., Prager, R., Luger, A., Pacher, R., & Clodi, M.
- Affiliations
- Medical University of Vienna (AT)
- TU Dortmund University (DE)
- Klinik Hietzing (AT)
- Corresponding author
- Pacher, Richard
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 62
- Issue
- 15
- Pages
- 1365-1372
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2113538868
- Cited by
- 385
- References
- 29
- Citations by year
- 2026: 43 · 2025: 41 · 2024: 43 · 2023: 34 · 2022: 39 · 2021: 30 · 2020: 28 · 2019: 22 · 2018: 24 · 2017: 26 · 2016: 26 · 2015: 14 · 2014: 11 · 2013: 3
- FWCI
- 12.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Universität Wien
- Medizinische Universität Wien
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- NT-proBNP, type 2 diabetes, renin-angiotensin system inhibitors, beta-blockers, cardiovascular hospitalization, cardiovascular mortality, heart rate reduction, blood pressure reduction, cardiovascular risk stratification, all-cause hospitalization
- MeSH terms
- Aged, Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Diabetes Mellitus, Type 2, Female, Heart Diseases, Heart Rate, Hospitalization, Humans, Male, Peptide Fragments, Primary Prevention, Prospective Studies, Biomarkers, Natriuretic Peptide, Brain, Kaplan-Meier Estimate, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
